Drug intelligence / Profile preview

NN3206

Development stage: Unknown
Lead developer: Novelty Nobility
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NN3206 is a first-in-class antibody-drug conjugate (ADC) developed by Novelty Nobility. It is designed to target an undisclosed RAS-correlated antigen, with the aim of treating neoplasms, specifically Pan-RAS-mutated solid tumors. The drug utilizes advanced ADC technology, combining a monoclonal antibody with a cytotoxic payload via a specialized linker. As of June 2025, NN3206 remains in the discovery phase and has not yet entered clinical trials or received regulatory approval. Its mechanism of action is presumed to involve selective targeting and killing of cancer cells expressing the RAS-correlated antigen[1][2][4][9].

Beyond the preview

Go deeper on NN3206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NN3206.

Explore the full profile